Innovus Pharmaceuticals will launch a fluticasone propionate nasal spray under the brand name FlutiCare in the US by the end of 2017 after acquiring rights to the product from West-Ward Pharmaceuticals International Limited (WWPIL). The 50μg per spray FlutiCare is equivalent to GSK’s Flonase, and the company said that it expects revenue from sales of the product in the range of $10-15 million in the first year of sales.
Innovus had previously announced the acquisition of an ANDA for FlutiCare when it acquired Novalere in 2015. In May 2016, the company said that it had signed a manufacturing agreement for the product in anticipation of approval of the ANDA, which it expected in the third quarter of that year; however, the ANDA currently remains under review.
The company said that it entered into the agreement with WWPIL instead of waiting for approval of the original ANDA in order to expedite the launch of the product in the US.
Innovus Pharma President and CEO Bassam Damaj commented, “Having an approved ANDA drug in our product portfolio in a very large indication and being one of only three national brands in the US is a great and long awaited achievement for Innovus Pharma. We are putting significant efforts into the launch of FlutiCare in the US in the second half of this year through our Beyond Human sales and marketing platform, our other on-line channels, and select retail store sales channels.”
Read the Innovus Pharma press release.
